Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that has completed Phase II clinical trial to treat oral mucositis in head and neck cancer.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone609-538-8200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$5.24 million
Profitability
Miscellaneous
Employees14
Next Earnings Date11/8/2019 (Estimated)
OptionableNot Optionable
Soligenix (NASDAQ:SNGX) Frequently Asked Questions
What is Soligenix's stock symbol?
Soligenix trades on the NASDAQ under the ticker symbol "SNGX."
How were Soligenix's earnings last quarter?
Soligenix, Inc. (NASDAQ:SNGX) released its quarterly earnings data on Tuesday, August, 13th. The biopharmaceutical company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.02. The biopharmaceutical company had revenue of $1.50 million for the quarter, compared to analysts' expectations of $1.40 million. Soligenix had a negative return on equity of 142.37% and a negative net margin of 173.58%. View Soligenix's Earnings History.
When is Soligenix's next earnings date?
What price target have analysts set for SNGX?
1 brokerages have issued 12-month price objectives for Soligenix's stock. Their predictions range from $4.00 to $4.00. On average, they expect Soligenix's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 273.8% from the stock's current price. View Analyst Price Targets for Soligenix.
What is the consensus analysts' recommendation for Soligenix?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Soligenix in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Soligenix.
Has Soligenix been receiving favorable news coverage?
Media coverage about SNGX stock has been trending positive this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Soligenix earned a news impact score of 2.5 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the company's share price in the next several days. View News Stories for Soligenix.
Who are some of Soligenix's key competitors?
Some companies that are related to Soligenix include Chembio Diagnostics (CEMI), Relmada Therapeutics (RLMD), Aquinox Pharmaceuticals (AQXP), Catalyst Biosciences (CBIO), Kezar Life Sciences (KZR), Trevi Therapeutics (TRVI), Avadel Pharmaceuticals (AVDL), Trevena (TRVN), Arbutus Biopharma (ABUS), Cumberland Pharmaceuticals (CPIX), Selecta Biosciences (SELB), Ovid Therapeutics (OVID), Catabasis Pharmaceuticals (CATB), Vaccinex (VCNX) and ASLAN PHARMACEU/ADR (ASLN).
What other stocks do shareholders of Soligenix own?
Who are Soligenix's key executives?
Soligenix's management team includes the folowing people:
- Dr. Christopher J. Schaber, Chairman, CEO & Pres (Age 53)
- Ms. Karen R. Krumeich, CFO, Sr. VP & Corp. Sec. (Age 65)
- Dr. Oreola Donini, Sr. VP & Chief Scientific Officer (Age 47)
- Dr. Richard C. Straube, Sr. VP & Chief Medical Officer (Age 67)
- Mr. Richard L. Dunning, Exec. Officer (Age 73)
Who are Soligenix's major shareholders?
Soligenix's stock is owned by many different of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (2.10%). Company insiders that own Soligenix stock include Christopher J Schaber, Jerome B Zeldis, Mark E Pearson and Spa Essetifin. View Institutional Ownership Trends for Soligenix.
Which major investors are buying Soligenix stock?
SNGX stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc.. Company insiders that have bought Soligenix stock in the last two years include Christopher J Schaber, Jerome B Zeldis, Mark E Pearson and Spa Essetifin. View Insider Buying and Selling for Soligenix.
How do I buy shares of Soligenix?
Shares of SNGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Soligenix's stock price today?
One share of SNGX stock can currently be purchased for approximately $1.07.
How big of a company is Soligenix?
Soligenix has a market capitalization of $21.72 million and generates $5.24 million in revenue each year. The biopharmaceutical company earns $-8,900,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis. Soligenix employs 14 workers across the globe.View Additional Information About Soligenix.
What is Soligenix's official website?
How can I contact Soligenix?
Soligenix's mailing address is 29 EMMONS DRIVE SUITE B-10, PRINCETON NJ, 08540. The biopharmaceutical company can be reached via phone at 609-538-8200 or via email at [email protected]
MarketBeat Community Rating for Soligenix (NASDAQ SNGX)
MarketBeat's community ratings are surveys of what our community members think about Soligenix and other stocks. Vote "Outperform" if you believe SNGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
